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1. Introduction 
Dramatic hemodynamic alterations occur during a normal, healthy pregnancy with the 
kidneys playing a major role to ensure that these adaptive changes occur properly. 
Therefore, it is not surprising that a significant number of women may develop new onset 
renal dysfunction or exacerbation of preexisting renal disease during pregnancy. Perhaps 
the most commonly encountered gestational disorder is hypertension, which can lead to 
significant complications for both the mother and the fetus when left untreated. A variety of 
factors may cause or contribute to the development or worsening of hypertension during 
pregnancy; nevertheless, clinically, hypertensive disorders of pregnancy can be divided into 
four major categories as recommended by the National High Blood Pressure Education 
Program Working Group on High Blood Pressure in Pregnancy: preeclampsia, 
chronic/preexisting hypertension, preeclampsia superimposed upon chronic hypertension, 
and gestational hypertension [1]. Of particular importance in defining these categories is the 
time of onset of hypertension during pregnancy, whether the women had preexisting 
hypertension prior to pregnancy, and whether proteinuria is present. Hypertension prior to 
pregnancy or occurring before 20 weeks of gestation indicates chronic/preexisting 
hypertension while hypertension occurring after 20 weeks of gestation but without 
proteinuria defines gestational hypertension. Preeclamspia is gestational hypertension with 
the additional feature of proteinuria. Of these hypertensive disorders of pregnancy, 
preeclampsia is the most common and can cause devastating systemic consequences 
including substantial renal injury. In this chapter, we discuss the pathologic manifestations 
and molecular pathologenesis of preeclampsia with a special emphasis on the renal effects 
of this disease. 
2. Clinical definition, epidemiology, and presentation 
Preeclamspia is a systemic syndrome of pregnancy defined by new onset hypertension 
(systolic ≥140 mmHg or diastolic ≥90 mmHg) and proteinuria of ≥0.3 grams per 24-hour 
occurring after 20 weeks of gestation in a previously normotensive woman [1, 2]. The 
incidence of preeclampsia is somewhat variable depending on the study population, but 
estimates generally range from 3 to 7% of all pregnancies [3-6], making it the leading cause 
of maternal and fetal morbidity and mortality and perhaps the most frequently encountered 
glomerular disease worldwide. Many factors have been associated with an increased risk of 
developing preeclampsia including prior history or family history of preeclampsia, 
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nulliparity, multigestational pregnancy, long time interval between pregnancies, obesity, 
age >40 years, diabetes mellitus, and preexisting history of other medical conditions such as 
chronic hypertension and renal disease, among others [7-10]. 
Preeclampsia can be subdivided into mild and severe, with severe forms exhibiting more 
prominent signs and symptoms of end-organ damage that may result in life-threatening 
disease. Multiple organ systems may be affected in severe preeclampsia including 
dysfunction of the central nervous system (i.e. blurred vision, altered mental status, severe 
headache, cerebrovascular accident), liver (i.e. elevated serum transaminases), 
cardiovascular system (i.e. systolic blood pressure ≥160 mm Hg or diastolic ≥110 mm Hg), 
lungs (i.e. pulmonary edema, cyanosis), and/or kidneys (i.e. proteinuria of ≥5 grams in 24 
hours, oliguria of <500 mL in 24 hours) [1, 11]. Other notable disease features include 
potential manifestation of microangiopathic hemolytic anemia, thrombocytopenia, and 
severe fetal growth restriction [12]. Preeclampsia with concurrent symptom of grand mal 
seizures with no other attributable cause supports the diagnosis of eclampsia. HELLP 
syndrome, a life-threatening variant of preeclampsia, may develop in approximately 10 to 
20% of women with severe preeclampsia [13]. The additional laboratory findings of 
microangiopathic hemolysis, elevated liver enzymes, and a low platelet count 
(thrombocytopenia) establish the diagnosis of HELLP syndrome and represent more 
prominent and systemic end-organ injury.  
Typically, women with preeclampsia display mild proteinuria; however, nephrotic range 
proteinuria and slight hematuria may be seen in severe preeclampsia and represents a 
significantly increased risk for complications [11]. Although edema can be present in 
preeclamptic patients, normal pregnancies often will induce edema, making this finding 
unreliable for the diagnosis of preeclampsia. A dramatic decrease in glomerular filtration 
rate may occur in preeclampsia although serum creatinine is generally close to baseline 
levels or may be slightly elevated. Acute renal failure is highly unusual. Other potential 
clinical features include hyperuricemia and hypercalciuria. 
Since renal diseases, especially those of glomerular origin, often present with 
hypertension and proteinuria, the clinical differential diagnosis of preeclampsia is broad 
and includes various glomerular diseases. Chronic glomerulonephritis, minimal change 
nephrotic syndrome, focal segmental glomerulosclerosis, membranous nephropathy, 
postinfectious glomerulonephritis, diabetic nephropathy, and sickle cell nephropathy 
should be considered. In severe cases of preeclampsia with significant microangiopathic 
hemolytic anemia and thrombocytopenia, hemolytic-uremic syndrome (HUS) and 
thrombotic thrombocytopenic purpura (TTP) should also be included in the differential 
diagnosis [12]. 
3. Pathologic findings 
Although preeclampsia is a clinical diagnosis based on new onset hypertension and 
proteinuria, as mentioned earlier, the specificity of these features is low and a renal 
biopsy may be helpful to confirm the suspicion of preeclampsia. Since many other forms 
of renal diseases may arise during pregnancy, the utility of the renal biopsy is also to 
exclude (or include) other pathologic processes of the kidney that may mimic 
preeclampsia clinically. 
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Typically, preeclampsia manifests morphologically as thrombotic microangiopathy 
(TMA) on renal biopsy, a pattern of renal injury commonly seen in association with 
endothelial cell injury. It should be stressed that TMA is a histologic and ultrastructural 
pattern that develops in response to renal injury and is not a specific disease. Many 
etiologies of TMA exist, including but not limited to TTP, HUS, malignant hypertension, 
scleroderma/systemic sclerosis, drugs/medications, antibody-mediated rejection (in 
allografts), and preeclampsia/eclampsia. Although a few subtle morphologic features 
appear to be seen more often in renal biopsies from patients with preeclampsia 
(discussed below); overall, these findings remain relatively non-specific and are not 
entirely reliable as morphologic indicators to distinguish preeclampsia from other 
etiologies of TMA. 
3.1 Light microscopy 
Since TMA is a disease that results from small vessel endothelial cell injury, the major 
morphologic findings reside within the glomeruli and/or the arterioles, the hallmark of 
which is that of fibrin platelet thrombi within these small vessels. However, unlike other 
etiologies of TMA, preeclampsia typically does not exhibit platelet fibrin thrombi within 
glomerular capillary lumina. Instead, the most characteristic glomerular feature of 
preeclampsia is that of prominent glomerular endothelial cell swelling, termed 
endotheliosis. This process results in occlusion of the glomerular capillary lumina without 
an appreciable increase in cellularity and generally gives the glomerular tuft a lobularly 
accentuated appearance (Figure 1). Overall, glomerular volume is slightly increased, yet 
since glomerular cellularity remains relatively unchanged, an impression of somewhat 
hypocellular glomeruli that take on a “bloodless” appearance is classically described in 
preeclampsia due to the endotheliosis. Variable degrees of mesangiolysis are commonly 
noted, but significant mesangial matrix widening or mesangial hypercellularity is not 
typically present. The glomerular tuft may also often exhibit capillary loop wrinkling with 
mild collapse/shrinkage of the glomerular tuft characteristic of acute ischemic changes. This 
feature is frequently seen in association with severe arteriolar changes in the afferent 
arteriole and most likely is due to hypoperfusion of the glomeruli from compromised 
arteriolar blood flow. Prominence of the visceral epithelial cells may be observed due to 
proteinuria; however, this finding may be quite variable and may, to a certain degree, 
depend on the severity of the proteinuria. The glomeruli can be either segmentally or 
globally involved, and the kidney may be focally or diffusely affected, depending on the 
severity of the disease.  
In chronic stages of TMA (including preeclampsia), the glomeruli typically display 
extensive glomerular capillary basement membrane replication, a feature similar to the 
“tram tracking” seen in membranoproliferative glomerulonephritis (MPGN) or in 
transplant nephropathy of renal allografts. Therefore, this morphologic feature is non-
specific and is a consequence of long term glomerular endothelial cell injury. However, 
unlike MPGN where subendothelial immune deposits are present on 
immunofluorescence and electron microscopy and sometimes can even be appreciated 
on light microscopy, chronic stages of TMA show no evidence of an immune complex-
mediated process. In allografts, chronic changes of TMA are indistinguishable from 
transplant glomerulopathy. 
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Arteriolar pathology is also often present along with the glomerular changes. Arterioles 
commonly display striking intimal swelling/edema with substantial luminal closure. Fibrin 
platelet thrombi and/or schisctocytes may be seen within the narrowed lumina. As 
mentioned earlier, this feature may markedly compromise afferent blood flow into the 
glomeruli resulting in glomerular ischemia. In the subacute phase, the intimal swelling 
becomes replaced by scarring. At first, appreciable numbers of cells are seen within the early 
intimal concentric scar giving an "onion skin" appearance. As scarring becomes more 
established, intimal fibroplasia sets in and is essentially indistinguishable from severe 
arteriolosclerosis seen in other etiologies of chronic vascular disease. 
3.2 Immunofluorescence microscopy 
Immunofluorescence microscopy shows no specific features for TMA or TMA as a result of 
preeclampsia. Fibrin, IgM, and to a lesser extent, complement components, may be positive 
within glomeruli along the capillary walls, in the mesangium, and in arterioles especially 
during acute stages of the disease, the latter of which corresponds to intravascular fibrin 
platelet thrombi seen on light microscopic evaluation [14-16]. The immunofluorescence 
intensity somewhat correlates to the severity/activity of the disease [15]. Although TMA can 
show fibrin positivity within the glomerular intracapillary lumina, preeclampsia rarely 
displays this finding. IgG is minimally positive if present, and IgA is usually negative. 
3.3 Electron microscopy 
Similar to the light and immunofluorescence microscopic findings, ultrastructural 
characteristics of TMA are similar regardless of the etiology. In the acute phase, electron 
microscopic examination of renal tissue from patients with TMA (including those with 
preeclampsia) reveal thickening of the glomerular capillary walls due to a combination of 
subendothelial widening, endothelial cell swelling, and occasional mesangial cell interposition. 
Often, the widened subendothelial space, represented as an expanded lamina rara interna, 
takes on a pale and flocculent appearance with irregular collections of slightly electron-dense 
material, typically without appreciable fibrin. Similar material can occasionally be seen within 
the mesangium, resulting in mesangial prominence with slight mesangial cell swelling. 
Electron-dense immuno-type deposits should be absent, and if present, should prompt further 
investigation into an immune complex-mediated process instead of or concurrent with TMA. 
As mentioned above, one slightly more distinguishing feature of preeclampsia is that of 
endotheliosis or endothelial cell swelling, which can be observed occluding much of the 
glomerular capillary lumina in severe cases (Figure 2). The endothelial cells in this instance 
lose their characteristic fenestrations. Although rarely seen in preeclampsia, intracapillary 
thrombi containing amorphous osmiophilic material admixed with fibrin, platelets, deformed 
red blood cells, and inflammatory cells can be present in other forms of TMA. Finally, 
podocyte foot processes often show at least focal, if not widespread, effacement. 
In chronic stages, nonspecific glomerular capillary basement membrane wrinkling and 
thickening may be appreciated. Often, new glomerular basement membrane material is also 
present giving rise to basement membrane reduplication and architectural “complexity”, 
features similar to that seen in transplant glomerulopathy in allograft kidney biopsies. 
Variable mesangial cell interposition can be observed. 
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Fig. 1. Preeclampsia, light microscopy. The glomerular capillary tufts are distended with 
closure of the capillary lumina due to swollen endothelial cells. The glomerular appearance 
is slightly lobular. (Jones’ methenamine silver, x400) (Courtesy of Dr. Patrick Walker and 
Nephropath, Little Rock, AK).  
4. Pathogenesis 
Microvascular endothelial cell injury appears to play a central role in the pathogenesis of 
preeclampsia. Therefore, as expected, end organ damage is generally directed towards 
organ systems highly dependent on the microvasculature for normal function including the 
kidney, liver, and central nervous system (including the eyes), among others. In order to 
fully comprehend the pathogenesis and renal consequences of preeclampsia, an 
understanding of renal physiology is required.  
4.1 Renal physiology 
 The kidneys act as filters that eliminate waste products within the blood, and thus, receive 
up to 25% of the cardiac output. To accomplish this function, systemic blood flow enters the 
kidneys and is directed into the glomeruli through the afferent arterioles. Filtration occurs 
through the glomerular capillary loops, which constitute the glomerular filtration barrier 
(GFB) and consist of the glomerular capillary basement membrane (GBM) flanked by 
visceral epithelial cells (also known as podocytes) on the side of the Bowman space and 
glomerular capillary endothelial cells along the glomerular capillary lumina (Figure 3). The 
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glomerular ultrafiltrate travels from the glomerular capillary lumina, through the 
endothelial cell fenestrations, through the GBM, and finally through the slit diaphragms 
between the podocyte foot processes, into the Bowman space. The integrity of the GFB 
prevents leakage of serum proteins into the Bowman space. However, when any component 
of the GFB is compromised, proteinuria arises.  
 
Fig. 2. Characteristic ultrastructural findings of preeclampsia. The glomerular capillary 
endothelial cells are swollen with occlusion of the capillary lumina. Note the significant 
effacement of the foot processes and the numerous protein resorption droplets within the 
visceral epithelial cells. (Electron microscopy, original magnification x4,800) 
The glomerular consequences of preeclampsia can be understood in terms of disruption of 
the GFB through glomerular capillary endothelial cell injury. Not only does endothelial 
damage result in endotheliosis and loss of endothelial cell fenestrations, the podocytes are 
disrupted as well since these remarkably specialized cells are highly dependent on signals 
derived from the glomerular endothelial cells to maintain foot process structure and the slit 
diaphragms. Ultimately, glomerular endothelial cell injury causes the breakdown of 
multiple components of the GFB, which leads to proteinuria and hypertension. Arteriolar 
endothelial injury also occurs in preeclampsia and may induce significant narrowing of 
arteriolar lumina. Consequently, glomerular filtration is compromised and results in 
glomerular hypoperfusion and diminished glomerular filtration rate with renal 
compensation manifesting as elevated blood pressure. 
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4.2 Molecular mechanism of preeclampsia 
Recently, extraordinary progress has been made in adding to our understanding of the 
molecular mechanism of preeclampsia. As mentioned earlier, the root of preeclampsia as a 
disease process lies in microvascular endothelial cell injury. Much of the data point to 
abnormal placentation or other causes of aberrant placental vascular development as the 
initiating event, which leads to placental hypoxia and subsequently triggers the release of 
placenta-derived factors into the maternal circulation. Consequently, these factors, most of 
which have antiangiogenic properties, cause damage to the microvascular endothelium by 
altering local angiogenic and vasodilatory signals. 
Several circulating factors have been implicated in the pathogenesis of preeclampsia, 
perhaps the best studied of which is soluble Flt-1 (sFlt1). This secreted form of vascular 
endothelial growth factor (VEGF) receptor-1 is able to bind and sequester angiogenic 
factors such as VEGFA and placental growth factor (PlGF), acting as an endogenous 
inhibitor of VEGF-receptor signaling. In preeclampsia, excessive levels of sFlt1, thought 
to originate from the placenta, appears to disrupt VEGF-receptor signaling, which is 
essential for the maintenance of endothelial health (Figure 3). As a result, tipping the 
endothelial environment towards an antiangiogenic state leads to generalized damage to 
the endothelium. In the glomeruli, glomerular endothelial cell injury results in 
disruption of the GFB with clinical consequences to the kidney as described earlier. In 
support of this mechanism of preeclampsia, several studies have shown that women 
with established preeclampsia display elevated levels of serum sFlt1 and that this 
increase may occur even before the onset of hypertension [17, 18]. Additionally, animal 
models overexpressing sFlt1 produce clinical signs and glomerular lesions reminiscent of 
human preeclampsia [17] . Similar observations have been reported in rodents when 
neutralizing antibodies to VEGFA are administered [19]. On the other hand, exogenous 
administration of VEGFA alleviates this preeclampsia-like phenotype in rats without 
apparent harm to the fetus [20]. Likewise, renal damage induced in mice by adenoviral 
overexpression of sFlt1 is alleviated by reducing circulating sFlt1 through co-expression 
of VEGF [21]. 
Some studies indicate that soluble endoglin (sEng) may act in a similar manner as sFlt1 in 
the pathogenesis of preeclampsia. Just as in the case of sFlt1, sEng likely produced by the 
placenta is also elevated in the sera of women with preeclampsia and correlates with disease 
severity [22, 23]. Interestingly, although overexpression of sEng alone in animal models 
gives only mild proteinuria when compared to sFlt1 overexpression, concurrent elevation of 
these factors leads to severe preeclampsia with evidence of HELLP syndrome [22]. The 
effects of sEng may be propagated through the disruption of transforming growth factor 
beta 1 (TGFB1) signaling with subsequent impairment of TGFB1-mediated activation of 
endothelial nitric oxide synthetase (eNOS) (Figure 3) [22]. Since eNOS is of prime 
importance in regulating vascular tone and also displays angiogenic properties, abrogation 
of eNOS as a result of elevated sEng levels induces endothelial cell injury and defects in 
vasodilatation. Of note, hypoxia up-regulates the placental expression of endoglin [24]. 
Therefore, placental hypoxia due to abnormal placentation may give rise to sEng elevation, 
and in combination with other antiangiogenic factors like sFlt1, may result in the 
development of preeclampsia or HELLP syndrome. 
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Fig. 3. VEGF produced by the podocytes is required to maintain healthy endothelial cells. 
Circulating sFlt1, likely originating from the placenta, is able to bind and sequester VEGF, 
resulting in endothelial cell damage. Similarly, the pro-endothelial effects of circulating 
TGF-β are inhibited by sEng, leading to endothelial injury. 
5. Prognosis and treatment  
At this time, delivery of the neonate and placenta is the only definitive cure of preeclampsia; 
however, fetal morbidity and mortality is highly dependent on the gestational age at the 
time of delivery. Therefore, a crucial decision must be made to weigh the benefits of 
delivery for the mother against the risks of prematurity for the neonate. Generally, quick 
resolution of both hypertension and proteinuria follows delivery.  
If delivery is not a viable option, management with antihypertensive medications and 
prophylactic seizure treatment with intravenous magnesium sulfate may be initiated [25-27]. 
If preterm delivery prior to 34 weeks is considered, betamethasone is commonly given to the 
mother to hasten fetal lung development [28]. In severe cases of preeclampsia/eclampsia 
where preterm delivery is not a viable option, maternal symptoms of significant 
microangiopathic hemolytic anemia, thrombocytopenia, renal failure, and/or neurologic 
abnormalities may be treated with plasma exchange with variable benefit [12]. 
Currently, treatment for preeclampsia is largely supportive, requiring careful obstetric 
management. As we make significant progress in elucidating the molecular mechanisms of 
preeclampsia, the hope of future targeted therapies to ameliorate or even prevent the 
development of preeclampsia appears to inch closer to reality. Given the immense health 
impact of preeclampsia due to its high worldwide prevalence, progress in this field has the 
potential to greatly improve global women’s health in a relatively short period of time. 
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